New imaging agent could sharpen bladder cancer detection
NCT ID NCT05321316
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study tests a new radioactive tracer called 68Ga-N188 that targets a protein called nectin-4, often found on urothelial cancer cells. Researchers will use PET/CT scans to see how well this tracer spots tumors in 20 people with recurrent or advanced bladder cancer. The goal is to improve imaging for better diagnosis and monitoring of the disease.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- 68Ga-N188 (a radioactive tracer for PET imaging)
- What this could lead to
- If successful, this could provide a more accurate way to detect and monitor urothelial carcinoma, especially in recurrent or advanced cases, potentially guiding better treatment decisions.
- What could go wrong
- This is a small, early-phase imaging study with only 20 participants, so results may not apply broadly. The probe's ability to improve patient outcomes over standard imaging is not yet proven.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for UROTHELIAL CARCINOMA are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Beijing Cancer Hospital
RECRUITINGBeijing, Beijing Municipality, 100142, China
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can a new nucleotide analogue boost cancer treatment?
- Can a Two-Pronged attack shrink Hard-to-Treat cancers?
- Can a Two-Drug attack shrink Hard-to-Treat bladder tumors?
- Could a lighter immunotherapy schedule keep advanced cancers in check?
- New biologic drug DBC-664 takes aim at Hard-to-Treat cancers
- New antibody aims to unlock immune attack on Hard-to-Treat cancers